By Jonathan Gardner
Published October 8, 2026
In a move designed to fortify its position as a global leader in specialized pain management, Viatris has announced a definitive agreement to acquire two key non-opioid pain assets from Pacira BioSciences. The deal, which brings high-performing commercial assets under the Viatris umbrella, highlights a calculated bet on the durability of non-opioid alternatives in an era where healthcare systems are aggressively seeking to reduce reliance on addictive analgesics.
The acquired portfolio, which generated nearly $700 million in revenue during the 2025 fiscal year, centers on Pacira’s flagship post-surgical pain drug, Exparel, and its osteoarthritis knee pain therapy, Zilretta. While the transaction offers immediate financial benefits, it also places Viatris at the center of a complex landscape involving patent litigation and the looming threat of generic competition.
Main Facts: The Strategic Rationale
The acquisition represents a cornerstone of Viatris’s "capital deployment strategy," a policy shift that prioritizes the acquisition of established, on-market assets that can provide immediate cash flow and long-term margin expansion.
Viatris is no stranger to the pain management sector. The company currently markets established brands such as Celebrex and Relpax. Furthermore, the company is awaiting a critical FDA decision by December 27, 2026, regarding a fast-acting formulation of meloxicam. By integrating Pacira’s products, Viatris is effectively building a "one-stop-shop" for surgical and chronic pain care, allowing for streamlined sales and marketing efforts across hospital and clinic networks.
Analysts have reacted favorably to the news. Leerink analyst Daniel Clark noted that the deal is expected to be "immediately accretive" to Viatris’s revenue, providing a stable growth engine that the company intends to sustain well into the 2030s.
Chronology: A Path to Acquisition
The journey toward this deal was paved by a series of legal and commercial milestones that have defined the trajectories of both companies:
- 2024: Pacira achieves a significant victory by securing new manufacturing patents for Exparel, which extended the theoretical intellectual property (IP) protections for the drug until 2044. This move was intended to insulate the drug from early generic entry.
- 2025: Exparel and Zilretta reach a combined annual revenue of nearly $700 million, solidifying their status as market leaders in their respective segments.
- Late 2025: Pacira enters into strategic patent settlements with Fresenius Kabi and a subsidiary of Hengrui Pharma, allowing for a phased entry of generic versions of Exparel beginning in 2030.
- September 2026: Daniel Clark initiates coverage on Pacira, highlighting that while Exparel has seen growth, it has historically been constrained by hospital formulary reluctance—a hurdle now beginning to clear with coverage from major insurers like UnitedHealthcare.
- October 8, 2026: Viatris officially announces the acquisition, signaling a new chapter for the management of the Pacira portfolio.
Supporting Data: Product Performance and IP Landscapes
The value of the acquisition is rooted in the specific pharmacology of the drugs involved. Both Exparel and Zilretta are proprietary, long-acting formulations of long-standing, generic non-opioid molecules—bupivacaine and triamcinolone, respectively.
Exparel: The Growth Engine
Exparel remains the crown jewel of the transaction. Despite its success, its market expansion has been a slow climb due to the traditional nature of hospital surgical protocols. The recent expansion of coverage by UnitedHealthcare was a watershed moment, suggesting that the clinical community is increasingly comfortable with the cost-benefit profile of the drug. However, the IP landscape remains turbulent. While the 2044 patent expiry provides a long-term buffer, the settlements with Fresenius Kabi and Hengrui Pharma permit them to capture "high single-digit" percentages of U.S. volume initially, scaling up to 30% within three years of their entry. Furthermore, other generic manufacturers are actively challenging these patents, creating a "watch-and-wait" scenario for investors.
Zilretta: The Chronic Care Component
Zilretta offers a stable, albeit shorter-term, value proposition. With patents set to expire in 2031, Viatris has approximately five years to maximize the reach of this therapy for osteoarthritis knee pain. Unlike the surgical market, the clinic-based environment for Zilretta requires a different sales approach, which Viatris is well-positioned to execute given its massive global distribution footprint.
Official Responses and Corporate Strategy
Viatris has been transparent about its intent to leverage its internal legal and commercial expertise to protect these assets. In a statement released Thursday, the company emphasized its "proven ability to extend product lifecycles and sustain meaningful sales."
For Viatris, the acquisition is not merely about adding volume; it is about "operational excellence." The company believes that by utilizing its internal resources, it can maintain market share for Exparel even as generic competitors enter the space. The strategy is to differentiate the branded version through superior support, clinical evidence, and established relationships with healthcare providers, even when a lower-cost generic alternative becomes available.
Pacira, meanwhile, transitions these assets into the hands of a company better equipped to manage the overhead of large-scale commercial operations. This allows Pacira to pivot its resources toward earlier-stage innovation or potential new pipeline candidates.
Implications: The Future of Pain Management
The acquisition holds significant implications for the broader pharmaceutical industry, particularly regarding how companies manage the "patent cliff" of successful non-opioid analgesics.
1. The Consolidation of Non-Opioid Pain Care
As the medical community continues to pivot away from opioid-based pain management due to regulatory pressure and public health concerns, the demand for sophisticated, long-acting non-opioid treatments is surging. By consolidating these assets, Viatris is positioning itself as a dominant player in this shift. If successful, the Viatris/Pacira portfolio could define the standard of care for surgical and chronic pain for the next decade.
2. The Economics of Patent Settlements
The deal highlights the changing nature of patent litigation. Companies are increasingly choosing to settle with generic entrants early, opting for a controlled, phased entry rather than the "all-or-nothing" risk of a trial. By accepting a limited generic entry in 2030, Viatris and its predecessors have effectively set a floor on the product’s decline, allowing for more predictable long-term financial modeling.
3. Investor Sentiment and Long-Term Value
For shareholders, the deal is a litmus test for Viatris’s strategy of "purchasing on-market, commercial assets." While some skeptics might point to the impending generic erosion, the consensus is that the cash flows generated between now and the mid-2030s will far outweigh the acquisition costs. The ability to grow earnings despite a shrinking patent window is a core competency Viatris is banking on to improve its valuation multiple.
4. The Hospital Formulary Challenge
A critical takeaway from the transaction is the importance of "formulary access." The success of drugs like Exparel is tethered to the willingness of hospital committees to include them in standard-of-care protocols. Viatris’s ability to secure broader institutional adoption will be the primary determinant of whether this deal meets its internal performance targets. The success with UnitedHealthcare is a positive signal, but the company must replicate this success across a broader spectrum of private and public payers.
5. Potential for Further M&A
Industry observers are closely watching to see if this acquisition signals a new wave of consolidation in the pain management space. As Viatris demonstrates its ability to integrate and manage these assets, other mid-to-large cap pharma companies may seek similar deals, viewing the non-opioid pain sector as a "safe harbor" for consistent revenue growth in an otherwise volatile drug development market.
Conclusion
The acquisition of the Pacira pain assets by Viatris is a classic example of late-lifecycle asset management. By combining proven, high-revenue products with a company that has the scale and expertise to navigate the complexities of patent expiration and formulary adoption, Viatris has effectively secured a stable revenue stream for the coming years. While the threat of generic competition is real and looming, the structured approach taken by the company suggests a high level of confidence in the long-term utility of the Exparel and Zilretta brands. As we look toward the 2030s, this deal will likely be viewed as a pivotal moment in the normalization of non-opioid pain management within the global healthcare market.
About the Author
